This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
UTHR vs. CTLT: Which Stock Is the Better Value Option?
by Zacks Equity Research
UTHR vs. CTLT: Which Stock Is the Better Value Option?
Catalent (CTLT) Expands Its Facility Capabilities in Germany
by Zacks Equity Research
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.
UTHR vs. CTLT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
UTHR vs. CTLT: Which Stock Is the Better Value Option?
UTHR or CTLT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
UTHR vs. CTLT: Which Stock Is the Better Value Option?
Why Is Catalent (CTLT) Up 0.4% Since Last Earnings Report?
by Zacks Equity Research
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalent's (CTLT) Latest Partnership to Boost Clinical Trials
by Zacks Equity Research
Catalent's (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to cancer patients.
Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up
by Zacks Equity Research
Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.
Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of -125% and 3.10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?
by Zacks Equity Research
Novo Nordisk's (NVO) revenues in the first quarter of 2024 are expected to have been driven by its diabetes and obesity care product sales, especially Ozempic, Rybelsus and Wegovy.
TAK or CTLT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TAK vs. CTLT: Which Stock Is the Better Value Option?
Charles River (CRL) Forges Collaboration With Ship of Theseus
by Zacks Equity Research
Charles River (CRL) is set to perform plasmid production for Ship of Theseus.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down
by Zacks Equity Research
Catalent (CTLT) reports lower revenues in Biologics segments in its second-quarter fiscal 2024, resulting in overall soft performance.
Catalent (CTLT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Catalent (CTLT) Rides on Acquisition Offer From Novo Holdings
by Zacks Equity Research
Catalent (CTLT) inks a merger agreement with Novo Holdings, under which the latter will acquire Catalent for $16.5 billion.
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) fiscal second-quarter results are likely to be driven by its non-COVID non-Sarepta Biologics business.
Strength Seen in Catalent (CTLT): Can Its 9.7% Jump Turn into More Strength?
by Zacks Equity Research
Catalent (CTLT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B
by Zacks Equity Research
Novo Nordisk (NVO) will acquire Catalent's three manufacturing sites from Novo Holdings to expand its manufacturing capacity.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Stock Market News for Jan 8, 2024
by Zacks Equity Research
Wall Street closed higher after a choppy session on Friday to finish the first week of 2024.
Recursion Pharmaceuticals (RXRX) Soars 7.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Catalent (CTLT) Up 4.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Catalent (CTLT) Stock for Now
by Zacks Equity Research
Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH